• Clinical and Experimental Pediatrics
• /
• 제56권1호
• /
• pp.8-12
• /
• 2013

Asthma is associated with increased levels of eosinophils in tissues, body fluids, and bone marrow. Elevated levels of eosinophil-derived neurotoxin (EDN) and eosinophil cationic protein (ECP) have been noted in asthma patients. Higher levels of EDN and ECP are also associated with exacerbated asthmatic conditions. Thus, EDN, along with ECP, may aid the diagnosis and monitoring of asthma. Several groups have suggested that EDN is more useful than ECP in evaluating disease severity. This may partially be because of the recoverability of EDN (not sticky, 100% recovery rate), as ECP is a sticky and more highly charged protein. In terms of clinical utility, EDN level is a more accurate biomarker than ECP when analyzing the underlying pathophysiology of asthma. As a monitoring tool, EDN has shown good results in children with asthma as well as other allergic diseases. In children too young to fully participate in lung function tests, EDN levels may be useful as an alter native measurement of eosinophilic inflammation. EDN can also be used in adult patients and in multiple specimen types (e.g., serum, sputum, bronchoalveolar lavage fluid, and nasal lavage fluid). These results are repeatable and reproducible. In conclusion, EDN may be a novel biomarker for the diagnosis, treatment, and monitoring of asthma/allergic disease.

• Allergy, Asthma & Immunology Research
• /
• 제10권6호
• /
• pp.686-697
• /
• 2018

Purpose: Several markers for eosinophilic inflammation have been proposed to predict response to asthma treatment. However, definitive criteria for treatment decisions have not yet been established. We investigate a potentially useful relatively non-invasive biomarker, eosinophil-derived neurotoxin (EDN), to predict favorable responses to budesonide or montelukast, common treatment for children with asthma. Methods: Young children (1 to 6 years old) were enrolled in this randomized, parallel, 2-group, open-label trial. Criteria for eligibility included: 1) being symptomatic during the run-in period; and 2) having a serum EDN (sEDN) level ${\geq}53ng/mL$, with positive specific immunoglobulin E to house dust mite. Eligible patients were randomly placed into 2 groups: the BIS group received budesonide inhalation suspension (BIS) 0.5 mg once daily; the MONT group received montelukast 4 mg once daily. Ineligible patients were invited to receive montelukast 4 mg once daily (OBS group). Treatment period was 12 weeks. Results: Asthma control days increased significantly in the BIS and MONT groups (P < 0.000) over the 12-week study period. There was no significant change in sEDN in the BIS group but there was a significant decrease in the MONT group (P < 0.000). Patients in the OBS group with high EDN levels (> 53 ng/mL) showed a significant decrease due to MONT treatment (P = 0.023). Rescue medication usage significantly decreased in the BIS and MONT groups (P < 0.000). Conclusions: EDN is a useful relatively non-invasive biomarker for predicting responses to montelukast and budesonide treatment of preschool children with beta2-agonist responsive recurrent wheeze and multiple-trigger wheeze (Trial registry at UMIN Clinical Trials Registry, UMIN000008335).

• 대한한방내과학회지
• /
• 제37권1호
• /
• pp.47-64
• /
• 2016

Objectives: In the present study, a genetic analysis was conducted to investigate the association of the expression of SNPs of EDN1 gene polymorphism with the clinical phenotype in bronchial asthma patients with either excess or deficiency syndrome.Methods: Ninety-four healthy control subjects and 52 asthma patients were included in this study. The asthma patients were divided into two groups: those with deficiency syndrome and those with excess syndrome. We searched the exonic and promoter areas of the EDN1 gene in the NCBI website SNPs with <0.01 minor allele frequency (MAF) and <0.01 heterozygosity. Pro programs were performed to obtain the odds ratio, 95% confidence interval, and p-value. Multiple logistic regression models were conducted to analyze the genetic data.Results: In our genotype and allele analyses, there were significant differences in the codominant 2 model of the rs3087459 SNP genotype and also in the CGG haplotype between the control group and the asthma group. Genotype and allele analyses were conducted between the deficiency and excess syndrome group. There were significant differences in the dominant and log-additive model and also in the frequency of C-alleles of rs3087459 SNP genotype. There were significant differences in codominant 1, dominant and log-additive model and T-allele of rs5370 SNP genotype. The AGG haplotype also revealed significant differences.Conclusions: EDN1 SNPs (rs3087459, rs5370) showed a significant association with symptomatic excess syndrome in Korean asthmatic patients.

• Restorative Dentistry and Endodontics
• /
• 제36권5호
• /
• pp.397-408
• /
• 2011

연구목적: 이 연구에서는 mineral trioxide aggregate 제재인 white ProRoot MTA (wMTA)와 수산화칼슘 제재인 Dycal을 인간치수세포에 적용한 후 치수세포의 분화와 증식, 석회화, 신생혈관형성(angiogenesis) 그리고 염증에 관여하는 유전자들의 발현 변화를 비교하였다. 연구 재료 및 방법: 실험군은 wMTA와 Dycal을 테플론 튜브(내경 10 mm, 길이 1 mm)에 담아 4시간 경화시킨 후 일차세포배양한 인간치수세포에 적용하였고, 대조군은 빈 튜브만을 적용하였다. 3시간, 6시간, 9시간, 24시간 후 total RNA를 추출하고 oligonucleotide microarray 방법을 통하여 유전자 발현 양상을 분석하였다. 위의 결과를 역전사 중합효소 연쇄반응(reverse transcriptase polymerase chain reaction)으로 재확인하였다. 결과: wMTA를 적용한 실험군에서 24,546개의 유전자 중 43개 유전자의 발현이 2배 이상 증가하였으며(예. BMP2, FOSB, THBS1, EDN1, IL11, COL10A1, TUFT1, HMOX1) 25개 유전자의 발현이 50% 이하로 감소하였다(예. SMAD6, TIMP2, DCN, SOCS2, CEBPD, KIAA1199). Dycal을 적용한 실험군에서 239개 유전자의 발현이 2배 이상 증가하였으며(예. BMP2, BMP6, SMAD6, IL11, FOS, VEGFA, PlGF, HMOX1, SOCS2, CEBPD, KIAA1199) 358개 유전자의 발현이 50% 이하로 감소하였다(예. EDN1, FGF). 결론: wMTA를 적용한 치수세포에서는 분화와 증식 그리고 석회화에 관여하는 유전자들의 변화가 관찰되었다. Dycal을 적용한 치수세포에서는 분화와 증식 그리고 신생혈관형성에 관여하는 유전자들의 변화가 관찰되었다. 또 Dycal이 염증에 관여하는 유전자들을 더 많이 발현시키는 양상을 보였다.

• Restorative Dentistry and Endodontics
• /
• 제35권3호
• /
• pp.152-163
• /
• 2010

이 연구에서는 mineral trioxide aggregate (MTA)를 in vitro로 인간치수세포에 적용하였을 때 유전자들의 변화를 조사하였다. 실험군은 MTA를 teflon tube (직경 10 mm 길이 2 mm)에 담아 4시간 경화시킨 후HDPCs에 적용하였고, 대조군은 빈tube만을 적용하였다. 6, 24, 72시간 후 total RNA를 추출하여 microarray를 이용하여 분석하여, 2배 이상 또는 절반 이하의 변화를 보이는 유전자 중 선택적으로 역전사 중합효소 연쇄반응(reverse transcriptase polymerase chain reaction)을 사용하여 발현을 확인하였다. 24,546개의 유전자 중에서 109개의 유전자가 2배 이상 up-regulation되었으며(예. FOSB, THBS1, BHLHB2, EDN1,IL11, FN1, COL10A1, TUFT1) 69개의 유전자가 50%이하로 down-regulation되었다(예. SMAD6, DCN). MTA는 bio-inert한 재료라기 보다는 치수세포에 다양한 경로로 영향을 주는 재료로 사료된다. 특히 치수세포의 분화와 증식에 관여하는 유전자의 변화에 영향을 주며 석회화 과정에 관여하는 유전자의 변화에 직접적인 영향을 주리라 사료된다.

• Parasites, Hosts and Diseases
• /
• 제43권1호
• /
• pp.33-37
• /
• 2005

Eosinophil degranulation is considered to be a key effector function for the killing of helminthic worms and tissue inflammation at worm-infected lesion sites. However, relatively little data are available with regard to eosinophil response after stimulation with worm-secreted products which contain a large quantity of cysteine proteases. In this study, we attempted to determine whether the degranulation of human eosinophils could be induced by the direct stimulation of the excretory-secretory products (ESP) of Paragonimus westermani, which causes pulmonary paragonimiasis in human beings. Incubation of eosinophils for 3 hr with Paragonimus-secreted products resulted in marked degranulation, as evidenced by the release of eosinophil-derived neurotoxin (EON) in the culture supernatants. Moreover, superoxide anion was produced by eosinophils after stimulation of the ESP. The ESP-induced EDN release was found to be significantly inhibited when the ESP was pretreated with protease inhibitor cocktail or the cysteine protease inhibitor, E-64. These findings suggest that human eosinophils become degranulated in response to P. westermani-secreted proteases, which may contribute to in vivo tissue inflammation around the worms.